[go: up one dir, main page]

WO2006076455A3 - Processes for preparing pyrazolo[3,4-d]pyrimidine ethers - Google Patents

Processes for preparing pyrazolo[3,4-d]pyrimidine ethers Download PDF

Info

Publication number
WO2006076455A3
WO2006076455A3 PCT/US2006/001020 US2006001020W WO2006076455A3 WO 2006076455 A3 WO2006076455 A3 WO 2006076455A3 US 2006001020 W US2006001020 W US 2006001020W WO 2006076455 A3 WO2006076455 A3 WO 2006076455A3
Authority
WO
WIPO (PCT)
Prior art keywords
processes
preparing pyrazolo
pyrimidine
pyrazolo
preparing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2006/001020
Other languages
French (fr)
Other versions
WO2006076455A2 (en
WO2006076455A8 (en
Inventor
Tawfik Gharbaoui
Dipanjan Sengupta
Edward A Lally
Naomi S Kato
Marlon Carlos
Natalie Rodriguez
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arena Pharmaceuticals Inc
Original Assignee
Arena Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to MX2007008381A priority Critical patent/MX2007008381A/en
Priority to EP06718131A priority patent/EP1838713A2/en
Priority to JP2007551363A priority patent/JP2008526975A/en
Priority to CA002593345A priority patent/CA2593345A1/en
Priority to AU2006204940A priority patent/AU2006204940A1/en
Priority to EA200701500A priority patent/EA013968B1/en
Priority to BRPI0606115-0A priority patent/BRPI0606115A2/en
Application filed by Arena Pharmaceuticals Inc filed Critical Arena Pharmaceuticals Inc
Publication of WO2006076455A2 publication Critical patent/WO2006076455A2/en
Publication of WO2006076455A8 publication Critical patent/WO2006076455A8/en
Publication of WO2006076455A3 publication Critical patent/WO2006076455A3/en
Priority to IL184365A priority patent/IL184365A0/en
Anticipated expiration legal-status Critical
Priority to NO20074052A priority patent/NO20074052L/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

The present invention relates to processes for preparing pyrazolo[3,4-d]pyrimidine ether compounds that are modulators of glucose metabolism and therefore useful in the treatment of metabolic disorders such as diabetes and obesity.
PCT/US2006/001020 2005-01-13 2006-01-12 Processes for preparing pyrazolo[3,4-d]pyrimidine ethers Ceased WO2006076455A2 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
BRPI0606115-0A BRPI0606115A2 (en) 2005-01-13 2006-01-12 processes for the preparation of pyrazol [3,4-d] pyrimidine ether compounds
JP2007551363A JP2008526975A (en) 2005-01-13 2006-01-12 Process for preparing pyrazolo [3,4-d] pyrimidine ethers
CA002593345A CA2593345A1 (en) 2005-01-13 2006-01-12 Processes for preparing pyrazolo[3,4-d]pyrimidine ethers
AU2006204940A AU2006204940A1 (en) 2005-01-13 2006-01-12 Processes for preparing pyrazolo[3,4-d]pyrimidine ethers
EA200701500A EA013968B1 (en) 2005-01-13 2006-01-12 Processes for preparing pyrazolo(3,4-d)pyrimidine ethers
MX2007008381A MX2007008381A (en) 2005-01-13 2006-01-12 Processes for preparing pyrazolo[3,4-d]pyrimidine ethers.
EP06718131A EP1838713A2 (en) 2005-01-13 2006-01-12 Processes for preparing pyrazolo[3,4-d]pyrimidine ethers
IL184365A IL184365A0 (en) 2005-01-13 2007-07-02 Processes for preparing pyrazolo[3,4-d]pyrimidine ethers
NO20074052A NO20074052L (en) 2005-01-13 2007-08-06 Processes for preparing pyrazole [3,4-D] pyrimidine ethers

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US64371205P 2005-01-13 2005-01-13
US60/643,712 2005-01-13

Publications (3)

Publication Number Publication Date
WO2006076455A2 WO2006076455A2 (en) 2006-07-20
WO2006076455A8 WO2006076455A8 (en) 2006-11-02
WO2006076455A3 true WO2006076455A3 (en) 2006-12-07

Family

ID=36463499

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/001020 Ceased WO2006076455A2 (en) 2005-01-13 2006-01-12 Processes for preparing pyrazolo[3,4-d]pyrimidine ethers

Country Status (22)

Country Link
US (1) US7425630B2 (en)
EP (1) EP1838713A2 (en)
JP (1) JP2008526975A (en)
KR (1) KR20070114126A (en)
CN (1) CN101142216A (en)
AR (1) AR052557A1 (en)
AU (1) AU2006204940A1 (en)
BR (1) BRPI0606115A2 (en)
CA (1) CA2593345A1 (en)
CR (1) CR9224A (en)
DO (1) DOP2006000009A (en)
EA (1) EA013968B1 (en)
GT (1) GT200600011A (en)
HN (1) HN2006001493A (en)
IL (1) IL184365A0 (en)
MX (1) MX2007008381A (en)
NO (1) NO20074052L (en)
PA (1) PA8659701A1 (en)
PE (1) PE20061118A1 (en)
TW (1) TW200637865A (en)
WO (1) WO2006076455A2 (en)
ZA (1) ZA200705279B (en)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10238722A1 (en) 2002-08-23 2004-03-11 Bayer Ag Improving attention, concentration, cognition, learning and/or memory performance, using selective phosphodiesterase 9A inhibitors, preferably 4H-pyrazolo-(3,4-d)-pyrimidin-4-one derivatives
HRP20050696B1 (en) 2003-01-14 2008-10-31 Arena Pharmaceuticals Inc. 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prpphylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia
US7132426B2 (en) * 2003-07-14 2006-11-07 Arena Pharmaceuticals, Inc. Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
US7923465B2 (en) * 2005-06-02 2011-04-12 Glenmark Pharmaceuticals S.A. Cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation
PE20091211A1 (en) 2007-11-30 2009-09-14 Boehringer Ingelheim Int PYRAZOLOPYRIMIDINE DERIVATIVES AS PDE9A MODULATORS
UA105362C2 (en) 2008-04-02 2014-05-12 Бьорингер Ингельхайм Интернациональ Гмбх 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators
WO2010009195A1 (en) * 2008-07-16 2010-01-21 Schering Corporation Bicyclic heterocycle derivatives and use thereof as gpr119 modulators
CA2736304A1 (en) 2008-09-08 2010-03-11 Boehringer Ingelheim International Gmbh Pyrazolopyrimidines and their use for the treatment of cns disorders
GEP20146098B (en) 2009-03-31 2014-05-27 Boehringer Ingelheim Int 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their usage as pde9a modulators
US20100285145A1 (en) * 2009-05-08 2010-11-11 Pfizer Inc Gpr 119 modulators
JP2012528847A (en) * 2009-06-05 2012-11-15 ファイザー・インク L- (piperidin-4-yl) -pyrazole derivatives as GPR119 modulators
SG182610A1 (en) 2010-01-27 2012-08-30 Arena Pharm Inc Processes for the preparation of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof
MX344770B (en) 2010-08-12 2017-01-06 Boehringer Ingelheim Int Gmbh * 6-cycloalkyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a inhibitors.
MX2013003184A (en) 2010-09-22 2013-06-07 Arena Pharm Inc Modulators of the gpr119 receptor and the treatment of disorders related thereto.
US8809345B2 (en) 2011-02-15 2014-08-19 Boehringer Ingelheim International Gmbh 6-cycloalkyl-pyrazolopyrimidinones for the treatment of CNS disorders
AU2012267556B9 (en) 2011-06-09 2017-05-11 Rhizen Pharmaceuticals Sa Novel compounds as modulators of GPR-119
JP6567276B2 (en) * 2014-05-13 2019-08-28 ソニーセミコンダクタソリューションズ株式会社 Solid-state imaging device and electronic device
HK1243936A1 (en) * 2014-12-06 2018-07-27 Intra-Cellular Therapies, Inc. Organic compounds
US11007175B2 (en) 2015-01-06 2021-05-18 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the S1P1 receptor
BR112017027656B1 (en) 2015-06-22 2023-12-05 Arena Pharmaceuticals, Inc. CRYSTALLINE HABIT OF SALT-FREE PLATE OF ACID L-ARGININE (R)-2-(7-(4- CYCLOPENTYL-3-(TRIFLUOROMETHYL)BENZYLOXY)- 1,2,3,4-TETRA-HYDROCYCLO-PENTA[B ]INDOL-3- IL)ACETIC, PHARMACEUTICAL COMPOSITION THAT COMPRISES IT, ITS USES AND METHOD OF PREPARATION THEREOF
CA3053418A1 (en) 2017-02-16 2018-08-23 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of primary biliary cholangitis
JP2019122134A (en) 2018-01-04 2019-07-22 Ntn株式会社 Pwm control device for power factor improvement of switching power supply
BR112020024762A2 (en) 2018-06-06 2021-03-23 Arena Pharmaceuticals, Inc. methods of treating conditions related to the s1p1 receptor
IL308071A (en) * 2021-06-23 2023-12-01 Hoffmann La Roche Process for the preparation of nlrp3 inhibitors

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0053678A1 (en) * 1980-12-05 1982-06-16 BASF Aktiengesellschaft 5-Amino-1-phenyl-4-cyano pyrazoles, herbicides containing them, process for their preparation and their use as herbicides
EP0772087A1 (en) * 1995-10-31 1997-05-07 Fuji Photo Film Co., Ltd. Pyrazolylazophenol dye
WO2003093269A2 (en) * 2002-05-02 2003-11-13 Bayer Cropscience Ag Substituted pyrazolo-pyrimidine-4-ones
US6660744B1 (en) * 1999-09-17 2003-12-09 Abbott Gmbh & Co. Kg Pyrazolopyrimidines as therapeutic agents
WO2004009602A1 (en) * 2002-07-23 2004-01-29 Smithkline Beecham Corporation Pyrazolopyrimidines as kinase inhibitors
WO2005007658A2 (en) * 2003-07-14 2005-01-27 Arena Pharmaceuticals, Inc. Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
WO2006050946A1 (en) * 2004-11-12 2006-05-18 Novartis Ag 1,4 substituted pyrazolopyrimidines as kinase inhibitors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0050671B1 (en) 1980-04-28 1985-03-20 Teijin Limited Thiazolo(3,2-a)pyrimidine derivatives, process for preparing same, and drug containing same
US4612376A (en) 1983-03-25 1986-09-16 Fujisawa Pharmaceutical Co., Ltd. Substituted-3,4-dihydro-4-(2,4,6-trimethoxyphenylimino)-2(1H)-pyrimidones useful as cardiotonic, antihypertensive, cerebrovascular vasodilator and anti-platelet agent
GB9114760D0 (en) 1991-07-09 1991-08-28 Pfizer Ltd Therapeutic agents
US6921763B2 (en) * 1999-09-17 2005-07-26 Abbott Laboratories Pyrazolopyrimidines as therapeutic agents

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0053678A1 (en) * 1980-12-05 1982-06-16 BASF Aktiengesellschaft 5-Amino-1-phenyl-4-cyano pyrazoles, herbicides containing them, process for their preparation and their use as herbicides
EP0772087A1 (en) * 1995-10-31 1997-05-07 Fuji Photo Film Co., Ltd. Pyrazolylazophenol dye
US6660744B1 (en) * 1999-09-17 2003-12-09 Abbott Gmbh & Co. Kg Pyrazolopyrimidines as therapeutic agents
WO2003093269A2 (en) * 2002-05-02 2003-11-13 Bayer Cropscience Ag Substituted pyrazolo-pyrimidine-4-ones
WO2004009602A1 (en) * 2002-07-23 2004-01-29 Smithkline Beecham Corporation Pyrazolopyrimidines as kinase inhibitors
WO2005007658A2 (en) * 2003-07-14 2005-01-27 Arena Pharmaceuticals, Inc. Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
WO2006050946A1 (en) * 2004-11-12 2006-05-18 Novartis Ag 1,4 substituted pyrazolopyrimidines as kinase inhibitors

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ANDREW J. PEAT ET ALL: "Novel pyrazolopyrimidine derivatives as GSK-3 inhibitors", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 14, 2004, pages 2121 - 2125, XP002399434 *
CHENG AND ROBINS: "Potential Purine Antagonists. XII. Synthesis of 1-Alkyl(aryl)-4,6-disubstituted Pyrazolo[3,4-d]pyrimidines", J. ORG. CHEM., vol. 23, 1958, pages 852 - 861, XP002385022 *
CHENG C C ET AL: "POTENTIAL PURINE ANTAGONISTS", JOURNAL OF ORGANIC CHEMISTRY, AMERICAN CHEMICAL SOCIETY. EASTON, US, vol. 21, 1 November 1956 (1956-11-01), pages 1240 - 1256, XP000575948, ISSN: 0022-3263 *
JAY A. MARKWALDER ET ALL: "Synthesis and Biological Evaluation of 1-Aryl-4,5-dihydro-1H-pyrazolo[3,4-d]pyrimidin-4-one Inhibitors of Cyclin-dependent Kinases", J.MED.CHEM., vol. 47, 2004, pages 5894 - 5911, XP002399637 *
MITSUNOBU O: "The use of diethyl azodicarboxylate and triphenylphosphine in synthesis and transformation of natural products", SYNTHESIS, GEORG THIEME VERLAG, STUTTGART, DE, 1981, pages 1 - 28, XP002123593, ISSN: 0039-7881 *

Also Published As

Publication number Publication date
EA013968B1 (en) 2010-08-30
ZA200705279B (en) 2008-11-26
CA2593345A1 (en) 2006-07-20
DOP2006000009A (en) 2006-08-15
CR9224A (en) 2007-10-23
JP2008526975A (en) 2008-07-24
BRPI0606115A2 (en) 2009-06-02
AR052557A1 (en) 2007-03-21
MX2007008381A (en) 2007-09-07
CN101142216A (en) 2008-03-12
NO20074052L (en) 2007-09-12
EA200701500A1 (en) 2007-12-28
IL184365A0 (en) 2007-10-31
WO2006076455A2 (en) 2006-07-20
EP1838713A2 (en) 2007-10-03
WO2006076455A8 (en) 2006-11-02
US7425630B2 (en) 2008-09-16
GT200600011A (en) 2006-08-10
AU2006204940A1 (en) 2006-07-20
PA8659701A1 (en) 2006-09-08
PE20061118A1 (en) 2006-10-13
HN2006001493A (en) 2010-08-19
TW200637865A (en) 2006-11-01
US20060154940A1 (en) 2006-07-13
KR20070114126A (en) 2007-11-29

Similar Documents

Publication Publication Date Title
WO2006076455A3 (en) Processes for preparing pyrazolo[3,4-d]pyrimidine ethers
WO2008070692A8 (en) Bicyclic compounds and use as antidiabetics
GEP20094828B (en) Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto
WO2007127505A3 (en) Use of sulfonamide derivatives in the treatment of disorders of the metabolism and the nervous system
IL204693A0 (en) Imidazo[1, 2 - a] pyrimidine derivatives for the treatment of diseases such as diabetes
WO2008008887A3 (en) Gpr119 agonists for treating metabolic disorders
MX2007007174A (en) Cycloalkylamine derivatives.
WO2005086860A3 (en) Methods for generating insulin-producing cells
AU2009278929A8 (en) Pyrazolo [3,4] pyrimidin-4-yl derivatives and their uses to treat diabetes and obesity
WO2004076413A3 (en) Phenyl- and pyridylpiperidine-derivatives as modulators of glucose metabolism
WO2006055511A3 (en) Stable tablet formulation of tetrahydrobiopterin
PL1743882T3 (en) Process for the preparation of isocyanates
WO2008012227A3 (en) Pyrazoles as glucokinase activators
TW200637844A (en) Processes for preparing aromatic ethers
WO2005103002A3 (en) Novel alkyne compounds with an mch-antagonistic action and medicaments comprising said compounds
WO2005089294A3 (en) Synthesis of indenoisoquinoliniums and methods of use
WO2006122777A3 (en) Use of 2,5-disubstituted thiazol-4-one derivatives in drugs
UA87026C2 (en) Processes for preparing pyrazolo[3,4-d]pyrimidine ethers
PL1720852T3 (en) Process for the preparation of enantiomerically pure 1-substituted-3-aminoalcohols
WO2009012930A3 (en) Process and product
WO2006113237A3 (en) Cd39l3 and its role in diabetes
WO2007070355A3 (en) Anti-inflammatory botanical products for the treatment of metabolic syndrome and diabetes
SG152296A1 (en) Novel process for the preparation of 5-amino-3h-thiazolo[4,5-d]pyrimidin-2- one
WO2007043094A3 (en) 6-vinyl pyrimidine and pyrimidinone derivatives and the use thereof
WO2006090265A3 (en) Processes for the preparation of levetiracetam, its intermediate and the use of levetiracetam in pharmaceutical compositions

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200680006454.3

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application
DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
ENP Entry into the national phase

Ref document number: 2593345

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2006204940

Country of ref document: AU

Ref document number: 556221

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 184365

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: CR2007-009224

Country of ref document: CR

WWE Wipo information: entry into national phase

Ref document number: 12007501466

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: MX/a/2007/008381

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2007551363

Country of ref document: JP

Ref document number: 2618/KOLNP/2007

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 1200701406

Country of ref document: VN

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2006204940

Country of ref document: AU

Date of ref document: 20060112

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 07075203

Country of ref document: CO

WWE Wipo information: entry into national phase

Ref document number: 2006718131

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 1020077018365

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 200701500

Country of ref document: EA

ENP Entry into the national phase

Ref document number: PI0606115

Country of ref document: BR

Kind code of ref document: A2